Parkinson disease (PD) produces progressive motor and cognitive impairments leading to dementia in ~75% of patients after 10 years. Development of therapies to slow PD progression requires validated biomarkers of pathologic processes and that predict progression. Such biomarkers could reflect regional pathophysiology and disruption of local or widely distributed networks that cause behavioral deficits. This project focuses on cross- sectional and longitudinal relationships among proteinopathy, cholinergic deficits, disruption of functional connectivity networks and behavior. We will build upon our findings in a single site longitudinal cohort of 270 people with PD and controls to extend and expand a multimodal approach to determine the time course of biomarker changes that correspond with and predict cognitive decline in PD. We have the potential to provide in vivo neuroimaging and CSF biomarkers of pathology and pathophysiology that could independently, or in combination, predict clinical manifestations in PD. We will combine PiB (an A? amyloid imaging agent) and VAT (a vesicular cholinergic transport ligand) PET, CSF protein levels and resting state functional connectivity analyses (rs-fcMRI using advanced analysis methods) measures of pathophysiology with sophisticated behavioral measures focusing on cognition and postmortem brain analyses including quantification of pathologic proteins. We will determine the relationships between PET biomarkers and CSF proteinopathy, and compare these to clinical manifestations. Rs-fcMRI, as a measure of brain function, will link brain pathology and neurochemistry with the associated clinical manifestations. In this manner, we will develop a strong mechanistic understanding of changes in these neuroimaging and CSF biomarkers and how this relates to cognitive decline and dementia in PD. This project holds great promise for identifying pathophysiological biomarkers for prediction of PD progression, patient stratification for trials and evaluation of new treatments.

Public Health Relevance

Parkinson disease (PD) is a progressive neurologic degenerative disease affecting nearly one million people in North America. These people have very high risk for development of dementia that adds substantial morbidity, mortality and economic burden to patients, families and society. This multimodal study will establish the time course of changes in a variety of biomarkers that is critical to design studies to slow PD progression and identify targets of engagement for new therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
2R01NS075321-06
Application #
9104629
Study Section
Clinical Neuroscience and Neurodegeneration Study Section (CNN)
Program Officer
Babcock, Debra J
Project Start
2011-05-01
Project End
2021-04-30
Budget Start
2016-05-01
Budget End
2017-04-30
Support Year
6
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Washington University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Milchenko, Mikhail; Snyder, Abraham Z; Campbell, Meghan C et al. (2018) ESM-CT: a precise method for localization of DBS electrodes in CT images. J Neurosci Methods 308:366-376
Hardt, Joshua I; Perlmutter, Joel S; Smith, Christopher J et al. (2018) Pharmacokinetics and Toxicology of the Neuroprotective e,e,e-Methanofullerene(60)-63-tris Malonic Acid [C3] in Mice and Primates. Eur J Drug Metab Pharmacokinet 43:543-554
Jin, Hongjun; Han, Junbin; Resing, Derek et al. (2018) Synthesis and in vitro characterization of a P2X7 radioligand [123I]TZ6019 and its response to neuroinflammation in a mouse model of Alzheimer disease. Eur J Pharmacol 820:8-17
Maiti, Baijayanta; Perlmutter, Joel S (2018) PET Imaging in Movement Disorders. Semin Nucl Med 48:513-524
Gratton, Caterina; Koller, Jonathan M; Shannon, William et al. (2018) Emergent Functional Network Effects in Parkinson Disease. Cereb Cortex :
Jinnah, H A; Comella, Cynthia L; Perlmutter, Joel et al. (2018) Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? Toxicon 147:89-95
Duncan, Ryan P; Van Dillen, Linda R; Garbutt, Jane M et al. (2018) Physical therapy and deep brain stimulation in Parkinson's Disease: protocol for a pilot randomized controlled trial. Pilot Feasibility Stud 4:54
Ibanez, Laura; Dube, Umber; Davis, Albert A et al. (2018) Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. Front Neurosci 12:230
Milchenko, Mikhail; Norris, Scott A; Poston, Kathleen et al. (2018) 7T MRI subthalamic nucleus atlas for use with 3T MRI. J Med Imaging (Bellingham) 5:015002
Liu, Hui; Jin, Hongjun; Luo, Zonghua et al. (2018) In Vivo Characterization of Two 18F-Labeled PDE10A PET Radioligands in Nonhuman Primate Brains. ACS Chem Neurosci 9:1066-1073

Showing the most recent 10 out of 100 publications